Objective To examine sources of repeat Chlamydia trachomatis infections using behavioural and molecular methods.
Methods Women with C trachomatis had baseline and 4-month follow-up visits consisting of behavioural surveys and genotyping of C trachomatis. Frequencies and population-attributable risk percentages (PAR%) were estimated for possible sources of repeat infections including sex partners not known to be treated, new sex partners, and sex partners not known to be monogamous. Women with different genotypes at baseline and follow-up were classified as different partner sources of infection.
Results The cumulative incidence of repeat infections in the sample (n=183) was 13% (95% CI 8% to 18%). Predictors of repeat infections included younger age and continued sex with a partner not known to be treated. Frequencies of having partners not known to be treated, new partners, or partners not known to be monogamous at follow-up were 21% (95% CI 15% to 27%), 37% (95% CI 30% to 44%) and 33% (95% CI 28% to 41%), respectively. The PAR% for having a partner not known to be treated was 26% (95% CI 3% to 49%) and for having a new sex partner was 21% (95% CI 0% to 50%). Among eight patients with available genotypes at baseline and follow-up, five had different genotypes and were classified as having a different partner source of infection.
Conclusions Different sex partner sources of repeat C trachomatis infections other than untreated sex partners may contribute substantially to the burden of repeat infections.
- Chlamydia trachomatis
- repeat infections
- ompA genotyping
- molecular typing
- risk behaviours
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Funding Sources of support for this work include The Donaghue Medical Research Foundation (Grant number DF03-040) and National Institutes of Health (Grant number P30NIMH62294— Center for Interdisciplinary Research on AIDS at Yale).
Competing interests None.
Patient consent Obtained.
Ethics approval This study was conducted with the approval of the Yale School of Medicine Human Investigation Committee (Protocol number 0402026363).
Provenance and peer review Not commissioned; externally peer reviewed.